Disorders of the autonomic nervous system are common in Parkinson's disease (PD). Earlier studies suggest that some nonmotor symptoms may fluctuate with the motor symptoms, but the possible interrelationship between motor phenomena and sweating has not been studied. The authors measured sweating by using an evaporimeter on three different areas of the body (right hand, left hand, chest) immediately before the morning PD medication (baseline), and thereafter hourly up to 4 hour, in 16 PD patients with wearing-off type of motor fluctuations and in 15 patients without clinical motor fluctuations. The clinical state of the patients was evaluated using the Unified Parkinson's Disease Rating Scale motor score every hour. Sweating increased during the 4-hour follow-up, and reached its maximum level at the time of the highest Unified Parkinson's Disease Rating Scale motor score phase (off-stage) in patients with wearing-off (initially affected hand, P = 0.007; left hand, P = 0.004; right hand, P = 0.034), but in the patients without wearing-off no changes in sweating were observed during the follow-up. Sweating of the left hand (P < 0.001), right hand (P < 0.001), and initially affected hand (P = 0.008) during the whole observation period was significantly higher in patients with motor fluctuations than in those without. The present study shows that sweating fluctuates in conjunction with wearing-off phenomenon.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mds.21422 | DOI Listing |
Neurol Sci
December 2024
Department of Neurology, General Hospital dr. Ivo Pedišić, Josipa Jurja Strossmayera 59, Sisak, 44000, Croatia.
Background: PRODUODOPA is a combination of foscarbidopa and foslevodopa indicated for the treatment of motor fluctuations in patients with advanced Parkinson's disease when available combinations of peroral drugs have not given satisfactory results. The solution is administered via subcutaneous infusion, most frequently in the abdomen, using an infusion pump. The study results showed a significant effect on the reductions in off time and higher control of motor symptoms without troublesome dyskinesia.
View Article and Find Full Text PDFClin Park Relat Disord
November 2024
Department of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Introduction: Zonisamide is a medication developed in Japan that is effective for motor symptoms and wearing off in Parkinson's disease (PD). Zonisamide has properties that may improve sleep disorders. The aim of this study is to verify the safety and efficacy of zonisamide for sleep disorders and rapid eye movement (REM) sleep behavioral disorders (RBD) using a mobile two-channel electroencephalography /electrooculography recording system in patients with PD.
View Article and Find Full Text PDFMult Scler Relat Disord
December 2024
IRCCS Neuromedicine, Pozzilli, IS 86077, Italy; Department of Human Neurosciences, Sapienza University of Rome, Rome 00185, Italy. Electronic address:
Background: Fatigue, depression and slow processing speed are debilitating symptoms in people with Relapsing-Remitting Multiple Sclerosis (RRMS) that significantly impacts on the quality of life. Natalizumab, a disease-modifying treatment, improves clinical symptoms but questions remain about the comparative efficacy between its standard interval dosing (SID) and extended interval dosing (EID) schedules.
Objective: To examine the impact of short term natalizumab dosing schedules-SID versus EID-on the so called "invisible symptoms", specifically focusing on symptom exacerbation during the 'wearing-off' phase before infusion and the subsequent relief post-infusion.
Mult Scler
November 2024
Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).
Objectives: We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.
Methods: We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.
PLoS One
October 2024
Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Background: Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice.
Methods: We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!